Verastem, Inc. (2VSA.F)
EUR 4.28
(-35.15%)
EUR 4.28
(-35.15%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -71.67 Million USD | -17.06% |
| 2021 | -61.15 Million USD | -28.66% |
| 2020 | -47.59 Million USD | 62.36% |
| 2019 | -126.42 Million USD | -39.29% |
| 2018 | -90.76 Million USD | -36.1% |
| 2017 | -66.68 Million USD | -83.55% |
| 2016 | -36.33 Million USD | 37.57% |
| 2015 | -58.19 Million USD | -9.44% |
| 2014 | -53.18 Million USD | -29.18% |
| 2013 | -41.16 Million USD | -28.55% |
| 2012 | -32.02 Million USD | -135.2% |
| 2011 | -13.61 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -7.06 Million USD | 78.41% |
| 2024 Q1 | -32.73 Million USD | -24.71% |
| 2023 Q3 | -18.87 Million USD | 18.5% |
| 2023 Q2 | -23.16 Million USD | -54.97% |
| 2023 Q1 | -14.94 Million USD | 7.08% |
| 2023 Q4 | -26.24 Million USD | -39.06% |
| 2022 Q1 | -16.9 Million USD | -2.64% |
| 2022 Q4 | -16.08 Million USD | 7.42% |
| 2022 Q3 | -17.37 Million USD | 18.48% |
| 2022 Q2 | -21.31 Million USD | -26.06% |
| 2022 FY | - USD | -17.06% |
| 2021 FY | - USD | -28.66% |
| 2021 Q2 | -15.86 Million USD | -13.23% |
| 2021 Q3 | -14.8 Million USD | 6.65% |
| 2021 Q4 | -16.47 Million USD | -11.25% |
| 2021 Q1 | -14 Million USD | 23.32% |
| 2020 Q3 | 15.27 Million USD | 173.87% |
| 2020 Q4 | -18.26 Million USD | -219.58% |
| 2020 Q2 | -20.67 Million USD | 22.88% |
| 2020 Q1 | -26.81 Million USD | 18.28% |
| 2020 FY | - USD | 62.36% |
| 2019 Q1 | -32.61 Million USD | -372.55% |
| 2019 Q2 | -36.44 Million USD | -11.76% |
| 2019 Q3 | -24.55 Million USD | 32.63% |
| 2019 FY | - USD | -39.29% |
| 2019 Q4 | -32.8 Million USD | -33.61% |
| 2018 FY | - USD | -36.1% |
| 2018 Q4 | -6.9 Million USD | 66.62% |
| 2018 Q2 | -17.18 Million USD | 15.95% |
| 2018 Q3 | -20.67 Million USD | -20.32% |
| 2018 Q1 | -20.44 Million USD | -15.0% |
| 2017 Q4 | -17.77 Million USD | 22.29% |
| 2017 FY | - USD | -83.55% |
| 2017 Q3 | -22.87 Million USD | -73.54% |
| 2017 Q2 | -13.18 Million USD | -2.62% |
| 2017 Q1 | -12.84 Million USD | -10.29% |
| 2016 Q4 | -11.64 Million USD | -47.44% |
| 2016 Q3 | -7.9 Million USD | 7.42% |
| 2016 Q1 | -8.25 Million USD | 29.92% |
| 2016 Q2 | -8.53 Million USD | -3.42% |
| 2016 FY | - USD | 37.57% |
| 2015 Q3 | -15.34 Million USD | -0.47% |
| 2015 Q4 | -11.77 Million USD | 23.28% |
| 2015 Q2 | -15.27 Million USD | -1.45% |
| 2015 Q1 | -15.05 Million USD | -8.98% |
| 2015 FY | - USD | -9.44% |
| 2014 Q3 | -13.28 Million USD | -2.13% |
| 2014 Q4 | -13.81 Million USD | -3.96% |
| 2014 Q1 | -13.07 Million USD | -15.35% |
| 2014 Q2 | -13.01 Million USD | 0.46% |
| 2014 FY | - USD | -29.18% |
| 2013 Q2 | -10.22 Million USD | -13.33% |
| 2013 Q1 | -9.02 Million USD | -14.02% |
| 2013 FY | - USD | -28.55% |
| 2013 Q4 | -11.33 Million USD | -7.08% |
| 2013 Q3 | -10.58 Million USD | -3.46% |
| 2012 Q1 | -6.88 Million USD | -15.08% |
| 2012 Q2 | -6.84 Million USD | 0.49% |
| 2012 Q3 | -10.37 Million USD | -51.55% |
| 2012 FY | - USD | -135.2% |
| 2012 Q4 | -7.91 Million USD | 23.73% |
| 2011 Q4 | -5.98 Million USD | -48.94% |
| 2011 Q3 | -4.01 Million USD | -61.57% |
| 2011 FY | - USD | 0.0% |
| 2011 Q2 | -2.48 Million USD | -116.84% |
| 2011 Q1 | -1.14 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| BioNTech SE | 1.08 Billion EUR | 106.59% |
| CureVac N.V. | -234.09 Million EUR | 69.381% |
| Biotest Aktiengesellschaft | 179 Million EUR | 140.042% |
| Biotest Aktiengesellschaft | 179 Million EUR | 140.042% |
| BRAIN Biotech AG | -2.38 Million EUR | -2902.723% |
| Formycon AG | 81.05 Million EUR | 188.43% |
| Heidelberg Pharma AG | -18.7 Million EUR | -283.158% |
| Medigene AG | -14.58 Million EUR | -391.43% |